| | Variables | HCC on NAFLD (n = 41) | HCC on HBV (n = 41) | value |
| | Demographic and clinical | | Age in years, mean (SD) | 67.4 (10.8) | 66.7 (11.1) | 0.854 | | Male gender, n (%) | 26 (63.4%) | 26 (63.4%) | 1.000 | | Diabetes, n (%) | 16 (39.0%) | 12 (29.3%) | 0.352 | | Ischemic cardiomyopathy, n (%) | 4 (9.8%) | 3 (7.3%) | 0.693 | | Liver function | | CTP class A, n (%) | 33 (80.5%) | 34 (82.9%) | 0.775 | | CTP class B, n (%) | 8 (19.5%) | 7 (17.1%) | 0.775 | | CTP class C, n (%) | 0 (0.0%) | 0 (0.0%) | — | | Tumor characteristics | | Size | | Largest nodule (cm), mean (SD) | 6.3 (3.4) | 7.1 (4.6) | 0.082 | | <2 cm, n (%) | 4 (9.8%) | 6 (14.6%) | 0.500 | | 2.1–3 cm, n (%) | 2 (4.9%) | 3 (7.3%) | 0.644 | | 3.1–5 cm, n (%) | 12 (29.3%) | 7 (17.1%) | 0.191 | | >5 cm, n (%) | 23 (56.1%) | 25 (61.0%) | 0.654 | | Number of nodules | | 1, n (%) | 26 (63.4%) | 27 (65.9%) | 0.817 | | 2–3, n (%) | 6 (14.6%) | 5 (12.2%) | 0.746 | | >3, n (%) | 9 (22.0%) | 9 (22.0%) | 1.000 | | Infiltrative, n (%) | 0 (0.0%) | 0 (0.0%) | — | | Milan out, n (%) | 26 (63.4%) | 25 (61.0%) | 0.820 | | Macrovascular infiltration, n (%) | 8 (19.5%) | 9 (22.0%) | 0.785 | | Detection on surveillance, n (%) | 31 (75.6%) | 36 (87.8%) | 0.153 | | Initial treatment modality | | TACE, n (%) | 21 (51.2%) | 19 (46.3%) | 0.825 | | Surgical resection, n (%) | 11 (26.8%) | 10 (24.4%) | 0.800 | | RFA, n (%) | 0 (0.0%) | 2 (4.9%) | 0.152 | | Sorafenib, n (%) | 3 (7.3%) | 4 (9.8%) | 0.693 | | Best supportive care, n (%) | 6 (15.0%) | 6 (14.6%) | 1.000 |
|
|
